BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1360 related articles for article (PubMed ID: 18514987)

  • 1. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Tentori F; Blayney MJ; Albert JM; Gillespie BW; Kerr PG; Bommer J; Young EW; Akizawa T; Akiba T; Pisoni RL; Robinson BM; Port FK
    Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineral metabolism and haemoglobin concentration among haemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Kimata N; Akiba T; Pisoni RL; Albert JM; Satayathum S; Cruz JM; Akizawa T; Andreucci VE; Young EW; Port FK
    Nephrol Dial Transplant; 2005 May; 20(5):927-35. PubMed ID: 15728270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study.
    Naves-Díaz M; Passlick-Deetjen J; Guinsburg A; Marelli C; Fernández-Martín JL; Rodríguez-Puyol D; Cannata-Andía JB
    Nephrol Dial Transplant; 2011 Jun; 26(6):1938-47. PubMed ID: 20513773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.
    Block GA; Klassen PS; Lazarus JM; Ofsthun N; Lowrie EG; Chertow GM
    J Am Soc Nephrol; 2004 Aug; 15(8):2208-18. PubMed ID: 15284307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis.
    Danese MD; Kim J; Doan QV; Dylan M; Griffiths R; Chertow GM
    Am J Kidney Dis; 2006 Jan; 47(1):149-56. PubMed ID: 16377396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study.
    Slinin Y; Foley RN; Collins AJ
    J Am Soc Nephrol; 2005 Jun; 16(6):1788-93. PubMed ID: 15814832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
    Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C;
    J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypercalcaemia is associated with poor mental health in haemodialysis patients: results from Japan DOPPS.
    Tanaka M; Yamazaki S; Hayashino Y; Fukuhara S; Akiba T; Saito A; Asano Y; Port FK; Kurokawa K; Akizawa T
    Nephrol Dial Transplant; 2007 Jun; 22(6):1658-64. PubMed ID: 17298993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associates of mortality and hospitalization in hemodialysis: potentially actionable laboratory variables and vascular access.
    Lacson E; Wang W; Hakim RM; Teng M; Lazarus JM
    Am J Kidney Dis; 2009 Jan; 53(1):79-90. PubMed ID: 18930570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.
    Fukagawa M; Kido R; Komaba H; Onishi Y; Yamaguchi T; Hasegawa T; Kurita N; Fukuma S; Akizawa T; Fukuhara S
    Am J Kidney Dis; 2014 Jun; 63(6):979-87. PubMed ID: 24119541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineral metabolism and mortality in dialysis patients: a reassessment of the K/DOQI guideline.
    Noordzij M; Korevaar JC; Dekker FW; Boeschoten EW; Bos WJ; Krediet RT; Bossuyt PM; Geskus RB;
    Blood Purif; 2008; 26(3):231-7. PubMed ID: 18305386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors modulating cytosolic calcium. Role in lipid metabolism and cardiovascular morbidity and mortality in peritoneal dialysis patients.
    Gadallah MF; el-Shahawy M; Andrews G; Ibrahim M; Ramdeen G; Hanna D; Gorospe W; Morkos A; Abbassian M; Moles K
    Adv Perit Dial; 2001; 17():29-36. PubMed ID: 11510292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study.
    Young EW; Albert JM; Satayathum S; Goodkin DA; Pisoni RL; Akiba T; Akizawa T; Kurokawa K; Bommer J; Piera L; Port FK
    Kidney Int; 2005 Mar; 67(3):1179-87. PubMed ID: 15698460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS).
    Bragg-Gresham JL; Fissell RB; Mason NA; Bailie GR; Gillespie BW; Wizemann V; Cruz JM; Akiba T; Kurokawa K; Ramirez S; Young EW
    Am J Kidney Dis; 2007 Mar; 49(3):426-31. PubMed ID: 17336704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of serum albumin and phosphorous as predictors of mortality in ESRD patients.
    Phelan PJ; O'Kelly P; Walshe JJ; Conlon PJ
    Ren Fail; 2008; 30(4):423-9. PubMed ID: 18569917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predialysis serum sodium level, dialysate sodium, and mortality in maintenance hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Hecking M; Karaboyas A; Saran R; Sen A; Hörl WH; Pisoni RL; Robinson BM; Sunder-Plassmann G; Port FK
    Am J Kidney Dis; 2012 Feb; 59(2):238-48. PubMed ID: 21944663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineral and bone disorder management in hemodialysis patients: comparing PTH control practices in Japan with Europe and North America: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Yamamoto S; Karaboyas A; Komaba H; Taniguchi M; Nomura T; Bieber BA; De Sequera P; Christensson A; Pisoni RL; Robinson BM; Fukagawa M
    BMC Nephrol; 2018 Oct; 19(1):253. PubMed ID: 30290781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Independent and joint associations of nutritional status indicators with mortality risk among chronic hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Lopes AA; Bragg-Gresham JL; Elder SJ; Ginsberg N; Goodkin DA; Pifer T; Lameire N; Marshall MR; Asano Y; Akizawa T; Pisoni RL; Young EW; Port FK
    J Ren Nutr; 2010 Jul; 20(4):224-34. PubMed ID: 20060319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of phosphorus and calcium-phosphorus product with mortality in CKD.
    Menon V; Greene T; Pereira AA; Wang X; Beck GJ; Kusek JW; Collins AJ; Levey AS; Sarnak MJ
    Am J Kidney Dis; 2005 Sep; 46(3):455-63. PubMed ID: 16129207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.